Brækhus assisted Swiss Diabetes Fund with its investment in Glucoset
Brækhus assisted Swiss Diabetes Venture Fund in connection with its investment in Glucoset, a Norway-based company specializing in glucose monitoring solutions for intensive care units.
Brækhus assisted Swiss Diabetes Venture Fund in connection with its investment in Glucoset, a Norway-based company specializing in glucose montitoring solutions for intensive care units.
Brækhus assisted Swiss Diabetes Venture Fund throughout the acquisition process, handling legal due diligence and SPA, along with a technical IP due diligence in collaboration with Onsagers.
Brækhus’ team was headed by Christoph Morck and Julius Kaasin.
The investment is mentioned in Finansavisen on November 24, 2023 (in Norwegian).
Swiss Diabetes Venture Fund is a Switzerland-based fund primarily focused on investing in health technology within the diabetes sector.
Contact
Christoph Morck
Partner
Commercial Contracts, Company Law, Construction, Defence, security and preparedness, M&A
